➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Merck
McKesson
Dow
Mallinckrodt
Medtronic

Last Updated: April 12, 2021

DrugPatentWatch Database Preview

VOLTAREN Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Voltaren, and what generic alternatives are available?

Voltaren is a drug marketed by Novartis and Glaxosmithkline Cons and is included in four NDAs.

The generic ingredient in VOLTAREN is diclofenac sodium. There are forty-seven drug master file entries for this compound. Ninety-one suppliers are listed for this compound. Additional details are available on the diclofenac sodium profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Voltaren

A generic version of VOLTAREN was approved as diclofenac sodium by ACTAVIS ELIZABETH on March 26th, 1996.

  Start Trial

Drug patent expirations by year for VOLTAREN
Drug Prices for VOLTAREN

See drug prices for VOLTAREN

Drug Sales Revenue Trends for VOLTAREN

See drug sales revenues for VOLTAREN

Recent Clinical Trials for VOLTAREN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Universiti Sains MalaysiaPhase 2
GlaxoSmithKlinePhase 3
Minia UniversityN/A

See all VOLTAREN clinical trials

US Patents and Regulatory Information for VOLTAREN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis VOLTAREN diclofenac sodium SOLUTION/DROPS;OPHTHALMIC 020037-001 Mar 28, 1991 AT RX Yes Yes   Start Trial   Start Trial   Start Trial
Novartis VOLTAREN diclofenac sodium TABLET, DELAYED RELEASE;ORAL 019201-003 Jul 28, 1988 DISCN Yes No   Start Trial   Start Trial   Start Trial
Novartis VOLTAREN diclofenac sodium TABLET, DELAYED RELEASE;ORAL 019201-001 Jul 28, 1988 DISCN Yes No   Start Trial   Start Trial   Start Trial
Novartis VOLTAREN diclofenac sodium TABLET, DELAYED RELEASE;ORAL 019201-002 Jul 28, 1988 DISCN Yes No   Start Trial   Start Trial   Start Trial
Novartis VOLTAREN-XR diclofenac sodium TABLET, EXTENDED RELEASE;ORAL 020254-001 Mar 8, 1996 DISCN Yes No   Start Trial   Start Trial   Start Trial
Glaxosmithkline Cons VOLTAREN ARTHRITIS PAIN diclofenac sodium GEL;TOPICAL 022122-001 Oct 17, 2007 OTC Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for VOLTAREN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis VOLTAREN diclofenac sodium SOLUTION/DROPS;OPHTHALMIC 020037-001 Mar 28, 1991   Start Trial   Start Trial
Novartis VOLTAREN diclofenac sodium SOLUTION/DROPS;OPHTHALMIC 020037-001 Mar 28, 1991   Start Trial   Start Trial
Novartis VOLTAREN diclofenac sodium TABLET, DELAYED RELEASE;ORAL 019201-003 Jul 28, 1988   Start Trial   Start Trial
Novartis VOLTAREN diclofenac sodium TABLET, DELAYED RELEASE;ORAL 019201-002 Jul 28, 1988   Start Trial   Start Trial
Novartis VOLTAREN diclofenac sodium SOLUTION/DROPS;OPHTHALMIC 020037-001 Mar 28, 1991   Start Trial   Start Trial
Novartis VOLTAREN diclofenac sodium TABLET, DELAYED RELEASE;ORAL 019201-001 Jul 28, 1988   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Merck
Colorcon
Boehringer Ingelheim
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.